HMD-HG-015-EN

Semaglutide: Long Duration, Clinical Potency and Metabolic Expansion

Milestone 15 | Incretin Historical Guideline Series

Contents

• Executive summary

• Historical context

• Scientific development of the milestone

• HMD figure: molecular architecture

• Documentary sequence

• HMD chronological table

• Independent HMD analysis

• Metabolic expansion

• Relationship with subsequent milestones

• References

Executive summary

Semaglutide represents a consolidation milestone within modern incretin history: it integrates long-duration molecular design, stability against metabolic degradation, once-weekly dosing and clinical expansion from type 2 diabetes toward obesity and cardiometabolic risk [1-7].

This document does not treat semaglutide as an isolated event, but as the result of a historical sequence: native GLP-1, DPP-4 resistance, acylation, albumin binding, SUSTAIN/PIONEER trials and transition toward STEP. From the HMD reading, semaglutide converted GLP-1 agonism into a high-impact metabolic and documentary platform [1,2,6].

1. Historical context

Previous milestones established that GLP-1 could stimulate insulin, inhibit glucagon, delay gastric emptying and modulate food intake. The pharmacological obstacle was to transform that biology into sustained, reproducible and clinically usable exposure. Semaglutide emerged at this point as a GLP-1 analogue designed for once-weekly action [1,2].

Semaglutide design relied on two pharmacological principles: protection against DPP-4 degradation and increased albumin affinity through acylation. The combination enabled prolonged exposure while preserving GLP-1 receptor agonist activity [1].

2. Scientific development of the milestone

In 2015, Lau and colleagues described the design strategy of once-weekly semaglutide, centred on increasing albumin affinity and securing metabolic stability. The objective was to overcome exposure limitations of native GLP-1 and shorter-duration formulations [1].

Subsequent clinical validation unfolded through the SUSTAIN programme. SUSTAIN 1 evaluated once-weekly semaglutide monotherapy in type 2 diabetes and documented effects on glycaemic control and body weight [3]. SUSTAIN-6 evaluated cardiovascular outcomes in high-risk patients with type 2 diabetes and placed semaglutide within a broader cardiometabolic reading [4].

The platform also extended to oral administration. PIONEER 6 evaluated oral semaglutide in cardiovascular outcomes and showed that the cardiovascular risk profile was not inferior to placebo in people with type 2 diabetes [5]. This expansion confirmed that semaglutide was not only a molecule, but an architecture of administration and exposure.

3. HMD figure: molecular architecture

Figure 1. HMD representation of the pharmacological architecture enabling weekly semaglutide exposure.

4. Documentary sequence

5. HMD chronological table

6. Independent HMD analysis

From the HMD reading, the semaglutide milestone is not defined only by potency or efficacy. Its importance lies in stabilizing a full architecture: long-duration molecule, potentially improved adherence through weekly dosing, glycaemic evidence, cardiometabolic signals and formal expansion toward obesity [1-7].

The transition from diabetes to obesity was not a simple commercial extension. It was a physiological consequence of previous milestones: satiety, intake, gastric emptying and postprandial control. Semaglutide served as the clinical vehicle that made these mechanisms visible at therapeutic scale [2,6,7].

7. Metabolic expansion

Figure 2. HMD synthesis of semaglutide expansion from type 2 diabetes toward cardiometabolic risk and obesity.

8. Relationship with subsequent milestones

Semaglutide prepares the ground for dual agonism and multiagonist systems. Once the capacity of GLP-1 agonism to intervene glucose, weight and metabolic risk was documented, the next logical question was whether combination with other incretin pathways, such as GIP, could expand the magnitude or quality of response. That question connects directly with tirzepatide and subsequent milestones.

References

1. Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler JC, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380.

2. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.

3. Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbol JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5(4):251-260.

4. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.

5. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851.

6. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.

7. Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.

8. U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. Silver Spring: FDA; 2025.